These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 33982338)

  • 21. Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene.
    Koppanati BM; Li J; Reay DP; Wang B; Daood M; Zheng H; Xiao X; Watchko JF; Clemens PR
    Gene Ther; 2010 Nov; 17(11):1355-62. PubMed ID: 20535217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.
    Alter J; Lou F; Rabinowitz A; Yin H; Rosenfeld J; Wilton SD; Partridge TA; Lu QL
    Nat Med; 2006 Feb; 12(2):175-7. PubMed ID: 16444267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice.
    Phelps SF; Hauser MA; Cole NM; Rafael JA; Hinkle RT; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 1995 Aug; 4(8):1251-8. PubMed ID: 7581361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
    Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
    Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition.
    Tanihata J; Nagata T; Ito N; Saito T; Nakamura A; Minamisawa S; Aoki Y; Ruegg UT; Takeda S
    Biochem Biophys Res Commun; 2018 Oct; 505(1):51-59. PubMed ID: 30236982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
    Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
    Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
    Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice.
    Xin C; Chu X; Wei W; Kuang B; Wang Y; Tang Y; Chen J; You H; Li C; Wang B
    Hum Mol Genet; 2021 Jun; 30(14):1349-1359. PubMed ID: 33987645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell transplantation-mediated dystrophin supplementation efficacy in Duchenne muscular dystrophy mouse motor function improvement demonstrated by enhanced skeletal muscle fatigue tolerance.
    Bourgeois Yoshioka CK; Takenaka-Ninagawa N; Goto M; Miki M; Watanabe D; Yamamoto M; Aoyama T; Sakurai H
    Stem Cell Res Ther; 2024 Sep; 15(1):313. PubMed ID: 39300595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene.
    Sakamoto M; Yuasa K; Yoshimura M; Yokota T; Ikemoto T; Suzuki M; Dickson G; Miyagoe-Suzuki Y; Takeda S
    Biochem Biophys Res Commun; 2002 May; 293(4):1265-72. PubMed ID: 12054513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mouse dystrophin muscle promoter/enhancer drives expression of mini-dystrophin in transgenic mdx mice and rescues the dystrophy in these mice.
    Anderson CL; De Repentigny Y; Cifelli C; Marshall P; Renaud JM; Worton RG; Kothary R
    Mol Ther; 2006 Nov; 14(5):724-34. PubMed ID: 16807118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
    Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
    Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current status and perspective of gene therapy on dystrophic animal model].
    Takeda S
    Rinsho Shinkeigaku; 2004 Nov; 44(11):911-3. PubMed ID: 15651329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression.
    Teichmann MD; Wegner FV; Fink RH; Chamberlain JS; Launikonis BS; Martinac B; Friedrich O
    PLoS One; 2008; 3(11):e3644. PubMed ID: 18982068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity.
    Trajanovska S; Ban J; Huang J; Gregorevic P; Morsch M; Allen DG; Phillips WD
    J Physiol; 2019 Sep; 597(18):4831-4850. PubMed ID: 31340406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice.
    Bostick B; Yue Y; Long C; Marschalk N; Fine DM; Chen J; Duan D
    Mol Ther; 2009 Feb; 17(2):253-61. PubMed ID: 19066599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.
    Ito K; Kimura S; Ozasa S; Matsukura M; Ikezawa M; Yoshioka K; Ueno H; Suzuki M; Araki K; Yamamura K; Miwa T; Dickson G; Thomas GD; Miike T
    Hum Mol Genet; 2006 Jul; 15(14):2266-75. PubMed ID: 16777842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Implication of Hinge 1 and Hinge 4 in Micro-Dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
    Wasala LP; Watkins TB; Wasala NB; Burke MJ; Yue Y; Lai Y; Yao G; Duan D
    Hum Gene Ther; 2023 May; 34(9-10):459-470. PubMed ID: 36310439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice.
    Gregorevic P; Blankinship MJ; Allen JM; Chamberlain JS
    Mol Ther; 2008 Apr; 16(4):657-64. PubMed ID: 18334986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.